301226-83-5

Basic information

• Product Name: 1-BOC-4-(PYRIDIN-2-YLAMINO)PIPERIDINE
• Synonyms: 1-BOC-4-(PYRIDIN-2-YLAMINO)PIPERIDINE
• CAS NO: 301226-83-5
• Molecular Formula: C₁₅H₂₃N₃O₂
• Molecular Weight: 277.366
• Mol File: 301226-83-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-4-(PYRIDIN-2-YLAMINO)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(PYRIDIN-2-YLAMINO)PIPERIDINE(301226-83-5)
• EPA Substance Registry System: 1-BOC-4-(PYRIDIN-2-YLAMINO)PIPERIDINE(301226-83-5)

Safety Data

• Hazardous Substances Data: 301226-83-5(Hazardous Substances Data)

Usage

Chemical compound

Piperidine derivative
It is a derivative of the piperidine ring, which is a common structural motif in many pharmaceutical compounds and organic molecules.

BOC protecting group

tert-butoxycarbonyl
The BOC group is attached to the nitrogen atom in the molecule, providing protection during chemical reactions and preventing unwanted side reactions.

Pyridin-2-ylamino group

Attached to the piperidine ring
This functional group is responsible for the unique reactivity and properties of the compound, making it a potential building block for the synthesis of various pharmaceutical compounds and organic molecules.

Reagent

Used in chemical reactions
1-BOC-4-(PYRIDIN-2-YLAMINO)PIPERIDINE is commonly used as a reagent in chemical reactions, facilitating the formation of new bonds and the synthesis of more complex molecules.

Starting material

Organic synthesis
It serves as a starting material in organic synthesis, allowing chemists to build upon its structure to create a wide range of compounds with diverse applications.

Pharmaceutical applications

Development and production of new drugs
Due to its unique structure and reactivity, 1-BOC-4-(PYRIDIN-2-YLAMINO)PIPERIDINE is important for the development and production of new drugs and other pharmaceutical products.

Potential uses

Building block for various organic molecules
Its unique structure and functional groups make it a valuable building block for the synthesis of a wide range of organic molecules with potential applications in various fields, including pharmaceuticals, materials science, and chemical research.

Upstream product

• 109-04-6 2-bromo-pyridine 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 504-29-0 2-aminopyridine 
• 301673-14-3 tert-butyl 4-iodopiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 206273-87-2 4-benzylamino-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

Copper-catalysed amination of alkyl iodides enabled by halogen-atom transfer

Despite the fact that nucleophilic displacement (SN2) of alkyl halides with nitrogen nucleophiles is one of the first reactions introduced in organic chemistry teaching, its practical utilization is largely limited to unhindered (primary) or ac

HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE

The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group; each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group; X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.

NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS

A subject of the invention is the compounds of formula (I): in which either R1 represents H, OH, NH2, —(CH2)m—NRaRb(m=0.1 or 2),Ra and Rb represent H, linear, branched or cyclic (C1 -C6) alkyl, (C3-C6) cycloalkyl-(C3-C6)— alkyl, Rc, S(O)2Rc, C(O)Rc, S(O)2Rd or C(O)Rd;or Ra and Rb with N form an Rc radical;Rc represents a saturated, unsaturated or 5- or 6-members aromatic ring, containing 1 to 4 heteroatoms chosen from N, O and S, optionally substituted;Rd represents a linear, branched or cyclic (C1-C6) alkyl, optionally substituted by 1 to 4 halogens;or R1 represents Rc or CHReRc or CHReRd;Re represents H, OH, NH2, NH—(C1-C6)-alk or N-(C1-C6)-alk2, or NH—(C1-C7)-acyl or NHRc;R2 represents H, (CH2)m—NRaRb, Rc, CHReRc or CHReRd, and R′2 represents H; it being understood that R1 and R2 cannot at the same time be H or that R1 and R2 or R2 and R1 cannot be one (CH2)m—NRaRb or Rc or H and the other one OH, or one H and the other one NH2, or one H and the other one (CH2)m—NRaRb in which Ra and Rb represent H or alkyl or C(O)Rd, in which Rd represents an unsubstituted alkyl or cycloalkyl; or R1 has the above definition except H and R2 and R′2 together represent gem dialkyl or alkyl-oxime, or R2 and R′2 represent respectively Rc or Rd and OH, NH2, NHRc or NHRf, Rf being a (C1-C7) acyl radical;or R1 represents H and R2 and R′2 together represent alkyl-oxime or one represents Rc and the other one represents OH, NH2, NHRc or NHRf;n is 0 or 1;R3 and R′3 represent H or (C1-C6) alkyl optionally substituted by 1 to 3 halogens or R3 represents (C1-C6) alkoxy carbonyl and R′3 represents H;R4 represents methyl optionally substituted by halogen;R5 represents H, (C1-C6) alkyl or (C7-C12) arylalkyl;R6 represents H, fluorine, NO2, CF3 or CN;in the form of enantiomers or mixtures, as well as their salts with acids and bases; their preparation and their application as anti-bacterials, in both human and veterinary medicine.

BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR

This invention is directed to a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula (I), a process of preparation of a compound of formula (I), a method o

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains

A new class of 4-(aminoheterocycle)piperidine derived 1,3,4 trisubstituted pyrrolidine CCR5 antagonists is reported. Compound 4a is shown to have good binding affinity (1.8 nM) and antiviral activity in PBMC's (IC95=50 nM). Compound 4a also has improved PK properties relative to 1.